Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Gtpbp2em1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Gtpbp2em1flox/Cya

Common Name
Gtpbp2-flox
Product ID
S-CKO-11934
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-56055-Gtpbp2-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Gtpbp2-flox Mouse (Catalog S-CKO-11934) were purchased from Cyagen.”
cKO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
Basic Information
Strain Name
Gtpbp2-flox
Strain ID
CKOCMP-56055-Gtpbp2-B6J-VA
Gene Name
Gtpbp2
Product ID
S-CKO-11934
Gene Alias
nmf205
Background
C57BL/6JCya
Gene Full Name
GTP binding protein 2
Modification
Conditional knockout
NCBI ID
56055 (Mouse)
Phenotype
MGI:1860138
Chromosome
Chr 17 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000024748
NCBI Transcript ID
NM_019581
Target Region
Exon 3~9
Size of Effective Region
~3.0 kb
Overview of Gene Research
Gtpbp2, a member of the G protein superfamily, encodes a guanosine triphosphate (GTP)-binding protein. It is involved in ribosomal homeostasis [2]. Gtpbp2 also participates in several signaling pathways, such as BMP and Wnt signaling, which are crucial for embryonic development. In Xenopus embryos, it is required for BMP signaling and mesoderm patterning, and is a positive regulator of Wnt signaling, maintaining low levels of the Wnt negative regulator Axin [3,5].

Biallelic loss-of-function variants in Gtpbp2 are associated with a neuro-ectodermal clinical presentation. Key features include prenatal onset microcephaly, tone and movement disorders, epilepsy, dysmorphic features, retinal dysfunction, ectodermal dysplasia, and brain iron accumulation [1]. Some aspects of the clinical presentation seem age-related, like brain iron accumulation appearing after childhood [1]. In a canine model, a homozygous in-frame deletion in Gtpbp2 causes non-syndromic progressive retinal atrophy [6]. In humans, mutations in Gtpbp2 lead to rare genetic diseases such as Jaberi-Elahi syndrome, characterized by intellectual disability, motor development delay, abnormal reflexes, skeletal abnormalities, and visual impairment [4].

In conclusion, Gtpbp2 is essential for ribosomal homeostasis and plays a vital role in multiple signaling pathways during development. Its loss-of-function variants are associated with various neuro-ectodermal and neurodegenerative disorders, highlighting its significance in understanding the mechanisms of these diseases.

References:
1. Carter, Melissa T, Venkateswaran, Sunita, Shapira-Zaltsberg, Gali, Kernohan, Kristin D, Boycott, Kym M. 2019. Clinical delineation of GTPBP2-associated neuro-ectodermal syndrome: Report of two new families and review of the literature. In Clinical genetics, 95, 601-606. doi:10.1111/cge.13523. https://pubmed.ncbi.nlm.nih.gov/30790272/
2. Salpietro, Vincenzo, Maroofian, Reza, Zaki, Maha S, Jepson, James E C, Houlden, Henry. 2023. Bi-allelic genetic variants in the translational GTPases GTPBP1 and GTPBP2 cause a distinct identical neurodevelopmental syndrome. In American journal of human genetics, 111, 200-210. doi:10.1016/j.ajhg.2023.11.012. https://pubmed.ncbi.nlm.nih.gov/38118446/
3. Kirmizitas, Arif, Gillis, William Q, Zhu, Haitao, Thomsen, Gerald H. 2014. Gtpbp2 is required for BMP signaling and mesoderm patterning in Xenopus embryos. In Developmental biology, 392, 358-67. doi:10.1016/j.ydbio.2014.05.008. https://pubmed.ncbi.nlm.nih.gov/24858484/
4. Manoochehri, Jamal, Shiri, Amirmasoud, Khoddam, Somayeh, Dianatpour, Mehdi, Tabei, Seyed Mohammad Bagher. 2024. Jaberi-Elahi syndrome: Exploring a novel GTPBP2 mutation and a literature review. In European journal of medical genetics, 70, 104953. doi:10.1016/j.ejmg.2024.104953. https://pubmed.ncbi.nlm.nih.gov/38852771/
5. Gillis, William Q, Kirmizitas, Arif, Iwasaki, Yasuno, Wyrick, Jonathan M, Thomsen, Gerald H. 2016. Gtpbp2 is a positive regulator of Wnt signaling and maintains low levels of the Wnt negative regulator Axin. In Cell communication and signaling : CCS, 14, 15. doi:10.1186/s12964-016-0138-x. https://pubmed.ncbi.nlm.nih.gov/27484226/
6. Murgiano, Leonardo, Niggel, Jessica K, Akyürek, Eylem Emek, Sacchetto, Roberta, Aguirre, Gustavo D. 2025. GTPBP2 in-frame deletion in canine model with non-syndromic progressive retinal atrophy. In Scientific reports, 15, 6079. doi:10.1038/s41598-025-89446-7. https://pubmed.ncbi.nlm.nih.gov/39971978/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research